The U.S. Food and Drug Administration (FDA) has announced the approval of pirtobrutinib, marketed as Jaypirca, specifically for adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

This approval provides healthcare professionals with an additional treatment option for managing these hematologic malignancies in their initial treatment phases.

Clinicians and healthcare providers are encouraged to consider this updated approval status when developing treatment plans for eligible patients diagnosed with CLL or SLL.